Ventana's CB 11
This article was originally published in The Gray Sheet
Executive Summary
Her-2/neu receptor overexpression test is "approvable" by FDA for use by physicians in deciding whether metastatic breast cancer patients should receive Genentech's monoclonal antibody-based drug Herceptin, President and CEO Chris Gleeson reports. The immunohistochemistry test developer expects to have the device on the U.S. market in early October